GILEAD SCIENCES, INC. (NASDAQ:GILD)
78.34 USD 
+0.69 (+0.89%)
Delayed Price / Updated:
4:00 PM EST, Dec 04, 2023 / Add to My Watchlist
Company Information
Financial Snapshot
| Annual | 12/2022FY | 12/2023FY |
|---|---|---|
| Total Revenue | $27.37 B | $27.09 B |
| Net Income | $6.23 B | $4.59 B |
| Quarterly | 3/31/2023 | 6/30/2023 |
| Total Assets | $61.88 B | $62.34 B |
| Total Liabilities | $41.24 B | $40.13 B |
| Operating Margin | 34.10% | 28.82% |
Address and Details
| Gilead Sciences, Inc.
333 Lakeside Drive |
|
| Industry | Biotechnology |
|---|---|
| Sector | Health Technology |
| Employees | 17,000 |
Business Summary
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Company Officers
| Mr. Daniel P. O'Day | Mr. Andrew D. Dickinson | Dr. Merdad V. Parsey | ||||||||||||||||||
| Chairman & Chief Executive Officer | Chief Financial Officer | Chief Medical Officer | ||||||||||||||||||
| Dr. Flavius Martin | Mr. Javier J. Rodriguez | Mr. Anthony Welters | Mr. Anthony Welters | Dr. Jeffrey A. Bluestone | Dr. Jeffrey A. Bluestone | Mr. Patrick E. Zeller | Mr. Kevin E. Lofton | Mr. Kevin E. Lofton | Ms. Kelly A. Kramer | Ms. Kelly A. Kramer | Dr. Jacqueline K. Barton | Dr. Jacqueline K. Barton | Mr. Harish M. Manwani | Mr. Harish M. Manwani | Mr. Daniel P. O'Day | Dr. Sandra J. Horning | Dr. Sandra J. Horning | Mr. Javier J. Rodriguez | Ms. Deborah H. Telman | |
| Executive Vice President-Research | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Director & Sr. Counsel | Lead Independent Director | Lead Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Chairman & Chief Executive Officer | Independent Director | Independent Director | Independent Director | Secretary, EVP-Corporate Affairs & General Counsel |
Revenue, Returns and Ratios
Total Revenue - TTM
;Total|Revenue(Prev%20Qtr)&BAR_VALUE_SUFFIX=B&YAXIS_LABEL_SUFFIX=B&BAR_WIDTH=90&BAR_VALUE_PREFIX=$&YAXIS_LABEL_PREFIX=$)
Ratios
;P/E|Ratio%20(FY);Debt/Equity|Ratio%20(MRQ)&BAR_VALUE_SUFFIX=&YAXIS_LABEL_SUFFIX=&BAR_WIDTH=55&YSEPLINES=2)
Revenue Summary - TTM
Return on Equity vs. Return on Assets
;Return%20on|Assests%20(MRQ)&BAR_VALUE_SUFFIX=%25&YAXIS_LABEL_SUFFIX=%25&BAR_WIDTH=90)
Per Share
;Cash%20Flow%20Per|Share%20(FY)&BAR_VALUE_SUFFIX=&YAXIS_LABEL_SUFFIX=&BAR_WIDTH=55&YSEPLINES=2)
Peer Comparison
| Company Name | Price | EPS (FY) | Annual Dividend | Book Value (FY) | Cash Flow (FY) |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $78.34 | 4.70 | 2.92 | 17.89 | 8.06 |
Latest News
More Headlines
Latest News
Market Data
Stock Watchlist
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.